Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 6/20 | 0.62 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 12/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369837 | 0.89 | NHERF1 (0.51) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL6374614 | 0.88 | KDM4E (0.49) | NHERF1MEN1KMT2ARXFP1 | |
| SCHEMBL6369287 | 0.86 | NPC1 (0.52) | NHERF1 | |
| SCHEMBL6368987 | 0.82 | NHERF1 (0.56) | NHERF1F7F3PYGLMEN1 | |
| SCHEMBL1308355 | 0.81 | NHERF1 (0.81) | NHERF1F7F3PYGLMEN1 | |
| SCHEMBL6369217 | 0.78 | NHERF1 (0.53) | NHERF1F7F3PYGLMEN1 | |
| SCHEMBL6369449 | 0.77 | KDM4E (0.52) | MEN1KMT2ARXFP1 | |
| SCHEMBL1310023 | 0.76 | NHERF1 (0.73) | NHERF1F7F3PYGLMEN1 | |
| SCHEMBL6369114 | 0.76 | NPC1 (0.48) | — | |
| SCHEMBL5401686 | 0.75 | NHERF1 (0.78) | NHERF1F7F3PYGLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | GAMMILL RONALD B (US) | 2005-01-27 | — | — | US | disclosed |
| US-6821977-B2 | SUBSTITUTED 1H-(INDOLE-2- CARBOXAMIDES AND 6H-THIENO(2,3-B)PYRROLE-5-CARBOXAMIDES USEFUL FOR INHIBITING GLYCOGEN PHOSPHORYLASE IN A MAMMAL | PFIZER, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030199553-A1 | Antidiabetic agents | GAMMILL RONALD B (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1340500-A1 | Antidiabetic agents | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199553-A1 | Antidiabetic agents | GPR119, IRS1, INSR | NHERF1 101/4885F7 1719/4885F3 2171/4885 |
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | PYGM, PYGL, IRS1 | NHERF1 2862/4885F7 4432/4885F3 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.